News Release - Callout Image

 

News Room

This page is designed to provide you with quick and easy access to key information about King Pharmaceuticals. Here you will find an archive of King news releases, information about our company and leaders and how to reach us.
If you cannot find what you’re looking for, please contact our Corporate Affairs department at 908-429-8350.

08/27/2008 Pain Therapeutics and King Pharmaceuticals Develop a New Abuse-Resistant Prescription Pain Medication
08/22/2008 King Proposes Acquisition of Alpharma for $33 Per Share in Cash
08/22/2008 King Pharmaceuticals Provides Updated Replay Information for Conference Call Regarding Proposed Acquisition of Alpharma
08/19/2008 Pain Therapeutics and King Pharmaceuticals Announce Final Data of Remoxy Phase III Study at World Pain Congress in Scotland
08/12/2008 FDA Accepts Remoxy® New Drug Application and Grants Priority Review
08/07/2008 King Pharmaceuticals Reports Second-Quarter 2008 Financial Results PDF File - 08-07-2008-2Q-2008-Earnings-Release-Comp.pdf
08/06/2008 King Pharmaceuticals Supports Time To Talk(™) Education Campaign
07/24/2008 King Pharmaceuticals Announces Date For Release Of Second-Quarter 2008 Financial Results And Conference Call
06/20/2008 King Pharmaceuticals to Present at Leerink Swann Pain Roundtable Conference
06/17/2008 Acurox™ Tablets Meet Primary Endpoint In Pivotal Phase III Study

 

pdf icon

Documents marked with this icon are presented in Portable Document Format (PDF) to retain the original format. To view or print this document, you must use the Adobe® Acrobat® Reader®. Acrobat® Reader® is free and available directly from Adobe’s Web site with full installation instructions. You can either view and print this document or save it to your computer’s hard drive to open later. Your method may vary depending on your operating system and browser type.

Get Acrobat

“Adobe” and “the Adobe logo” are either registered trademarks or trademarks of Adobe Systems Incorporated in the United States and/or other countries.